Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years

NCT01382329 is registered in ClinicalTrials.gov with Alachua Government Services, Inc. as lead sponsor.

NCT NCT01382329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01382329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years
Lead sponsor
Alachua Government Services, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
June 30, 2011
Completion date
May 31, 2012
Enrollment
340 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

h5n1 influenza